Financials data is unavailable for this security.
View more
Year on year Sanofi SA 's net income fell -35.49% from 8.37bn to 5.40bn despite relatively flat revenues. A contributing factor has been an increase in the percentage of sales devoted to the cost of goods sold from 30.17% to 30.65%.
| Gross margin | 69.33% |
|---|---|
| Net profit margin | 9.44% |
| Operating margin | 14.37% |
| Return on assets | -- |
|---|---|
| Return on equity | -- |
| Return on investment | -- |
More ▼
Cash flow in EURView more
In 2023, cash reserves at Sanofi SA fell by 4.03bn. However, the company earned 10.26bn from its operations for a Cash Flow Margin of 22.09%. In addition the company used 6.20bn on investing activities and also paid 8.05bn in financing cash flows.
| Cash flow per share | 5.37 |
|---|---|
| Price/Cash flow per share | 17.13 |
| Book value per share | -- |
|---|---|
| Tangible book value per share | -- |
More ▼
Balance sheet in EURView more
| Current ratio | -- |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | -- |
|---|---|
| Total debt/total capital | -- |
More ▼
Growth rates in EUR
Year on year, growth in dividends per share increased 5.62% while earnings per share excluding extraordinary items fell by -35.47%. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 3.90% |
|---|---|
| Div growth rate (5 year) | 4.14% |
| Payout ratio (TTM) | 104.42% |
| EPS growth(5 years) | 4.55 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -50.17 |
More ▼
